| Literature DB >> 25247425 |
Liz Carmem Silva-Pereira1, Carlos Alberto Machado da Rocha2, Luiz Raimundo Campos da Silva E Cunha1, Edmar Tavares da Costa3, Ana Paula Araújo Guimarães4, Thais Brilhante Pontes5, Domingos Luiz Wanderley Picanço Diniz6, Mariana Ferreira Leal7, Caroline Aquino Moreira-Nunes8, Rommel Rodríguez Burbano9.
Abstract
Mercury exhibits cytotoxic and mutagenic properties as a result of its effect on tubulin. This toxicity mechanism is related to the production of free radicals that can cause DNA damage. Methylmercury (MeHg) is one of the most toxic of the mercury compounds. It accumulates in the aquatic food chain, eventually reaching the human diet. Several studies have demonstrated that prolactin (PRL) may be differently affected by inorganic and organic mercury based on interference with various neurotransmitters involved in the regulation of PRL secretion. This study evaluated the cytoprotective effect of PRL on human lymphocytes exposed to MeHg in vitro, including observation of the kinetics of HL-60 cells (an acute myeloid leukemia lineage) treated with MeHg and PRL at different concentrations, with both treatments with the individual compounds and combined treatments. All treatments with MeHg produced a significant increase in the frequency of chromatid gaps, however, no significant difference was observed in the chromosomal breaks with any treatment. A dose-dependent increase in the mitotic index was observed for treatments with PRL, which also acts as a co-mitogenic factor, regulating proliferation by modulating the expression of genes that are essential for cell cycle progression and cytoskeleton organization. These properties contribute to the protective action of PRL against the cytotoxic and mutagenic effects of MeHg.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25247425 PMCID: PMC4199052 DOI: 10.3390/ijerph110909822
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Description of in vitro treatments with methylmercury chloride and prolactin on human healthy lymphocytes and HL-60 leukemic cell line.
| Treatment (T) | CH3HgCl [μΜ] | PRL [nΜ] | Doxorubicin * [μM] |
|---|---|---|---|
| T1 (C−) | - | - | - |
| T2 | 50 | - | - |
| T3 | 100 | - | - |
| T4 | 500 | - | - |
| T5 | 1000 | - | - |
| T6 | - | 1 | - |
| T7 | - | 10 | - |
| T8 | - | 100 | - |
| T9 | 50 | 10 | - |
| T10 | 500 | 10 | - |
| T11 | 50 | 100 | - |
| T12 | 500 | 100 | - |
| T13 | - | - | 0.010 |
CH3HgCl = methylmercury chloride; PRL = Prolactin; (C−) = Untreated; (*) = Positive control, used only for the HL60 cell line. Cells were harvested using centrifugation (300 g), treated for 10 min with 0.075 M KCl (Merck, Darmstadt, Germany), and fixed with 1:3 Carnoy fixative (glacial acetic acid:absolute methanol). Slides were prepared, air-dried, and stained for 5 min with 3% Giemsa stain (Merck) diluted in buffer solution, pH 6.8.
Relative frequency of healthy human lymphocytes with gaps, breaks, and gaps plus breaks after exposure to methylmercury chloride and prolactin.
| Treatment | Gaps | Breaks | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N° | FR (%) | N° | FR (%) | N° | FR (%) | ||||
| T1 = C− | 4 | 0.50 | 0 | 0.00 | 4 | 0.50 | (-) | ||
| T2 | 57 | 7.13 * | 2 | 0.25 NS | 59 | 7.38 * | (-) | ||
| T3 | 32 | 4.00 * | 2 | 0.25 NS | 36 | 4.50 * | (-) | ||
| T4 | 82 | 10.25 * | 3 | 0.38 NS | 87 | 10.88 * | (-) | ||
| T5 | 118 | 14.75 * | 4 | 0.50 NS | 122 | 15.25 * | (-) | ||
| T6 | 1 | 0.13 * | 0 | 0.00 NS | 1 | 0.13 * | (-) | ||
| T7 | 3 | 0.38 | 1 | 0.13 NS | 4 | 0.50 | (-) | ||
| T8 | 2 | 0.25 * | 0 | 0.00 NS | 2 | 0.25 * | (-) | ||
| T9 | 54 | 6.75 * | 2 | 0.25 NS | 56 | 7.00 * | |||
| T10 | 75 | 9.38 * | 1 | 0.13 NS | 76 | 9.50 * | |||
| T11 | 54 | 6.75 * | 1 | 0.13 NS | 55 | 6.88 * | |||
| T12 | 80 | 10.00 * | 2 | 0.25 NS | 82 | 10.25 * | |||
T = Treatment; C− = Negative Control; FR = Relative Frequency.; N° = Number. *P < 0.05 comparing to the negative control; **P< 0.05 comparing treatments. The Chi-Square test was used for proportions of abnormal cells, and the U Mann-Whitney test for the relative frequency of gaps and breaks (total number of changes per 100 cells). NS = not statistically significant. (-) = no comparison.
Distribution of cells with polyploid aberrations (%) following exposure to different concentrations of methylmercury chloride and prolactin.
| Treatment | Lymphocytes | Cell Line HL-60 | ||||||
|---|---|---|---|---|---|---|---|---|
| Polyploid Index (%) | Polyploid Index (%) | |||||||
| T1(C−) | 4.57 ± 2.2254 | (-) | 7.13 ± 1.2543 | (-) | ||||
| T2 | 21.71 ± 5.2509 * | (-) | 24.00 ± 5.6327 * # | (-) | ||||
| T3 | 37.14 ± 3.9761 * | (-) | 32.20 ± 3.2659 * # | (-) | ||||
| T4 | 42.86 ± 2.7343 * | (-) | 42.86 ± 2.3652 * # | (-) | ||||
| T5 | 60.14 ± 3.4365 * | (-) | 0.00 ± 0.0000 * # | (-) | ||||
| T6 | 3.43 ± 1.7183 | (-) | 5.15 ± 1.3266 | (-) | ||||
| T7 | 5.86 ± 1.9518 | (-) | 8.08 ± 1.9688 | (-) | ||||
| T8 | 9.00 ± 1.9149 | (-) | 10.00 ± 3.1255 | (-) | ||||
| T9 | 20.57 ± 1.6184 * | 22.42 ± 5.9644 * # | ||||||
| T10 | 38.14 ± 2.9114 * | 39.14 ± 3.9159 * # | ||||||
| T11 | 26.00 ± 2.7080 * | 25.24 ± 2.3650 * # | ||||||
| T12 | 35.86 ± 2.7946 * | 37.63 ± 5.6329 * # | ||||||
| T13(C+) | (-) | (-) | 6.33 ± 1.8247 * | (-) | ||||
Data are reported as the mean ± SD. *P < 0.05 compared to control (chi-square test); **P < 0.05 for data compared between treatments (chi-square test); #P < 0.05 compared to positive control—Doxorubicin 0.010 μM (chi-square test). NS = not statistically significant. (-) = no comparison.
Mean mitotic index (%) of healthy human lymphocytes and HL-60 leukemic cells treated with different concentrations of methylmercury chloride and prolactin.
| Treatment | Lymphocytes | Cell Line HL-60 | ||||||
|---|---|---|---|---|---|---|---|---|
| Mitotic Index (%) | Mitotic Index (%) | |||||||
| T1(C−) | 3.89 ± 0.6440 | (-) | 3.80 ± 0.3247 # | (-) | ||||
| T2 | 3.40 ± 0.5196 NS | (-) | 3.60 ± 0.5236 NS # | (-) | ||||
| T3 | 2.13 ± 0.3904 * | (-) | 3.30 ± 0.3934 NS # | (-) | ||||
| T4 | 1.60 ± 0.4000 * | (-) | 1.30 ± 0.5254 * | (-) | ||||
| T5 | 1.70 ± 0.5657 * | (-) | 0.00 ± 0.0000 * # | (-) | ||||
| T6 | 3.76 ± 0.5769 NS | (-) | 3.60 ± 0.4246 NS # | (-) | ||||
| T7 | 4.93 ± 0.6020 * | (-) | 4.00 ± 0.3639 NS # | (-) | ||||
| T8 | 5.43 ± 0.6499 * | (-) | 4.40 ± 0.5896 NS # | (-) | ||||
| T9 | 3.57 ± 0.5880 NS | 3.70 ± 0.3262 NS # | ||||||
| T10 | 2.66 ± 0.5381 * | 2.60 ± 0.3588 * | ||||||
| T11 | 3.64 ± 0.4577 NS | 4.20 ± 0.4856 NS # | ||||||
| T12 | 2.26 ± 0.3960 * | 2.90 ± 0.3699 * # | ||||||
| T13(C+) | (-) | (-) | 1.90 ± 0.4529 * | (-) | ||||
Data are reported as the mean ± SD. *P < 0.05 compared to control (chi-square test); **P < 0.05 for data compared between treatments (chi-square test); #P < 0.05 compared to positive control—Doxorubicin 0.010 μM (chi-square test); NS = not statistically significant; (-) = no comparison.
Figure 1Spearman’s correlations between MeHg concentration and mitotic index.
Figure 2Proposed mechanism for the cytoprotective activity of prolactin in antagonism to the cytotoxic and mutagenic effects of methylmercury.